title: Immunomodulation by Bordetella pertussis: antiviral effects.
abstract: Treatment of mice by intraperitoneal inoculation of pertussis vaccine or lipopolysaccharide extracted from B. pertussis will effect resistance to rabies virus, encephalomyocarditis virus, Semliki Forest virus, and Herpes simplex virus. Our previous observations indicated that treatment of C3H/HeN (+/nu) and BDF1 mice with pertussis vaccine injected i.p. five days prior to a mouse adenovirus lethal dose i.p. challenge elicited resistance to clinical disease and death. Susceptibility returned to a portion of the test population 35 days after pertussis vaccine treatment. The pertussis vaccine induced resistance developed in athymic (nude) mice also; however, the population succumbed to infection 35 days later. Titration of pertussis vaccine with respect to induction of resistance indicated the median effective dose (ED50) was approximately 25 micrograms dry weight. This report describes the antiviral activity of acellular components extracted from pertussis vaccine. Extraction of B. pertussis cells with 1.0M NaCl and ammonium sulfate fractionation (20-40% saturation) of the extract resulted in an acellular preparation that induced resistance to lethal dose mouse adenovirus infection. The resistance inducing activity was retained after treatment of the extract with detergent (GAF Emulphogene BC 720) to remove lipopolysaccharide and adsorption to alum gel. Comparison of endotoxin content of pertussis vaccine acellular fractions, polysaccharide fraction and purified lipopolysaccharide suggested that endotoxin probably plays a role in the induction of resistance. The endotoxin content of a Emulphogene-treated preparation that protected 80% of a test population was 39 ng. The lipopolysaccharide extracted from Escherichia coli, Vibrio cholerae, Salmonella typhimurium, and Salmonella minnesota did not induce a resistant state seven days after administration; however, lipopolysaccharide extracted from B. pertussis induced a resistant state.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: A L
authors.initials: AL
authors.lastname: Winters
authors.forename: D W
authors.initials: DW
authors.lastname: Baggett
authors.forename: J D
authors.initials: JD
authors.lastname: Lee
authors.forename: G L
authors.initials: GL
authors.lastname: Sloan
authors.forename: R D
authors.initials: RD
authors.lastname: Lemmon
authors.forename: R S
authors.initials: RS
authors.lastname: Stinson
mesh_terms: D000257:Adenoviridae Infections / Q000517:prevention & control*; D000276:Adjuvants, Immunologic; D000818:Animals; D000998:Antiviral Agents / Q000302:isolation & purification; D001426:Bacterial Proteins / Q000276:immunology / Q000302:isolation & purification; D001886:Bordetella pertussis / Q000276:immunology*; D005260:Female; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D010567:Pertussis Vaccine / Q000276:immunology; D010566:Virulence Factors, Bordetella / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D001426:Bacterial Proteins; D008070:Lipopolysaccharides; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella